潘霄羽,王燕,黃高翔,盧建,曲伸△
(1同濟大學附屬第十人民醫院內分泌代謝科,上海 200072;2第二軍醫大學病理生理教研室,上海 200433)
TGF-β1激活的p38 MAPK在TGF-β1上調人卵巢癌細胞PAI-1表達中的作用*
潘霄羽1,王燕2,黃高翔2,盧建2,曲伸1△
(1同濟大學附屬第十人民醫院內分泌代謝科,上海 200072;2第二軍醫大學病理生理教研室,上海 200433)
目的:纖溶酶原激活物抑制劑1(PAI-1)在凝血、創傷修復、炎癥和腫瘤轉移中起重要作用。已有報道轉化生長因子β1(TGF-β1)能通過Smad通路誘導PAI-1表達,但TGF-β1能否通過激活非Smad通路誘導PAI-1表達尚不清楚,因此本研究探討了在卵巢癌細胞中TGF-β1激活的非Smad通路p38絲裂原活化蛋白激酶(p38 MAPK)和細胞外信號調節激酶(ERK)與TGF-β1上調PAI-1表達的關系。方法:用10 μg/L TGF-β1處理卵巢癌SKOV3細胞和HO-8910細胞后,采用real-time PCR和Western blotting的方法檢測PAI-1的表達,用磷酸化p38 MAPK的抗體和磷酸化ERK的抗體檢測p38 MAPK和ERK的激活情況,用p38 MAPK和ERK的特異性抑制劑SB203580和PD98059分別抑制其活性后,檢測PAI-1的表達。結果:TGF-β1在卵巢癌細胞中可明顯上調PAI-1 mRNA和蛋白的表達,并可快速激活p38 MAPK和ERK。用p38 MAPK的抑制劑可以明顯抑制TGF-β1上調PAI-1表達,但是抑制ERK活性對TGF-β1上調PAI-1表達沒有明顯影響。結論:TGF-β1激活的p38 MAPK通路參與了TGF-β1上調PAI-1的表達。
轉化生長因子β1;纖溶酶原激活物抑制劑1;p38絲裂原活化蛋白激酶;細胞外信號調節激酶;卵巢腫瘤
纖溶酶原激活物抑制劑1(plasminogen activator inhibitor-1,PAI-1)能通過抑制纖溶酶原激活物進而抑制纖溶酶的生成,在凝血、創傷修復、炎癥和腫瘤轉移中起重要作用[1-3]。已知PAI-1在卵巢組織的不同細胞中都有表達,并且影響排卵后的傷口修復和卵巢癌的侵襲與轉移過程[4-5]。轉化生長因子β1 (transforming growth factor β1,TGF-β1)是一種分布廣泛,在細胞外基質形成、免疫和炎癥的調控以及腫瘤發生發展中起重要作用的細胞生長因子[6-7]。TGF-β1與其受體結合后,通過激活經典的Smad通路和非Smad通路導致生物效應[8-9]。已有報道TGF-β1能通過Smad通路誘導PAI-1表達[10],但我們前期在卵巢癌細胞中的研究表明,用RNA干擾的方法抑制Smad3的表達只能部分阻斷TGF-β1上調PAI-1的作用,提示TGF-β1激活的非Smad通路可能也參與了TGF-β1上調PAI-1的作用,因此本課題進一步探討了在卵巢癌細胞中TGF-β1激活的p38絲裂原活化蛋白激酶(p38 mitogen-activated protein kinase,p38 MAPK)和細胞外信號調節激酶(extracellular signal-regulated protein kinase,ERK)通路和TGF-β1上調PAI-1表達的關系,以進一步闡明TGF-β1上調PAI-1的機制。
1 主要試劑和藥品
重組人轉化生長因子β1(Peprotech);p38 MAPK抑制劑SB203580和ERK抑制劑PD98059(Sigma);小鼠抗人PAI-1單克隆抗體(Santa Cruz);兔抗人p38 MAPK多克隆抗體、兔抗人p-p38 MAPK多克隆抗體、兔抗人p-ERK多克隆抗體和兔抗人ERK多克隆抗體(Cell Signaling);小鼠抗人β-actin抗體(Sigma);山羊抗小鼠與山羊抗兔HRP標記的II抗(ROCKLAND)。
2 細胞系及其培養
人卵巢癌HO-8910細胞和SKOV3細胞用含有10%胎牛血清、1%雙抗的RPMI-1640培養基培養,置于37℃、飽和濕度和5%CO2細胞培養箱中培養。取對數生長期細胞進行實驗。
3 Real-time PCR
接種對數生長期的細胞于6孔板內,4×105cells/well,待細胞貼壁完全后用含5%去激素血清的RPMI 1640培養液培養12 h,之后給予TGF-β1(10 μg/L)處理細胞不同時間,用TRIzol法抽提細胞總RNA、定量和鑒定,行反轉錄,cDNA的合成按Thermo試劑盒說明書進行。反應條件依次為:25℃10 min,42℃1 h,72℃10 min,在PCR儀中進行。Real-time PCR用SYBR Green Real-Time PCR Master Mix試劑盒,參照試劑盒說明書步驟,在Eppendorf實時熒光定量PCR儀上完成。PAI-1上游引物為5’-GCCTCCAAAGACCGAAATGTG-3’,下游引物為5’-GTCGTTGATGATGAATCTGGCTC-3’;用GAPDH作為內參照,上游引物為5’-TAGCCCAGGATGCCCTTTAGT-3’,下游引物為5’-CCCCCAATGTATCCGTTGTG-3’。反應條件如下:94℃變性20 s,60℃退火20 s,72℃延伸45 s;反應40個循環。相對定量用2-△△Ct法計算。
4 Western blotting檢測蛋白質表達
用蛋白裂解液破碎細胞,并用超聲破碎儀冰上破碎細胞后加入等量上樣緩沖液,100℃水浴煮沸5 min,冰上冷卻后上樣。用10%SDS聚丙烯酰胺凝膠電泳分離蛋白質;用轉膜系統將蛋白轉移至PVDF膜上;常溫下用含5%脫脂奶粉的TBST封閉45 min,加入1∶1 000稀釋的I抗體,4℃搖床孵育過夜; TBST洗脫3次后,加入辣根過氧化物酶偶聯的II抗孵育1 h,TBST洗脫3次后,將PVDF膜浸泡于發光檢測試劑混合液后,于凝膠成像分析儀上檢測。
5 統計學處理
計量資料數據用均數±標準差(mean±SD)表示,組間均數比較采用單因素方差分析。所有實驗至少重復3次,全部數據采用SPSS 17.0統計軟件進行處理。以P<0.05為差異有統計學意義。
1 TGF-β1對人卵巢癌細胞PAI-1表達的影響
用TGF-β1(10 μg/L)處理卵巢癌SKOV3細胞和HO-8910細胞不同時間,real-time PCR結果顯示,TGF-β1能時間依賴性地上調PAI-1 mRNA表達,這種上調作用在4 h后達到最高,PAI-1 mRNA分別為對照組的6.1倍和3.8倍(P<0.01)(圖1A、B)。用Western blotting的方法也證實10 μg/L TGF-β1處理SKOV3和HO-8910細胞6 h后PAI-1蛋白增加(圖1C、D),表明在卵巢癌細胞中,TGF-β1能上調PAI-1的表達。
2 p38 MAPK與TGF-β1上調PAI-1的關系
Western blotting的結果顯示,在SKOV3和HO-8910細胞中,TGF-β1(10 μg/L)能快速誘導p38 MAPK的磷酸化,這種作用至少能持續4 h(圖2A、B),表明TGF-β1能快速激活人卵巢癌細胞p38 MAPK。用p38 MAPK抑制劑SB203580(10 nmol/L)預處理SKOV3細胞后,可以明顯減少TGF-β1上調PAI-1 mRNA的水平(P<0.05)(圖2C)。在HO-8910細胞中也得到了類似的結果(P<0.05)(圖2D)。表明在卵巢癌細胞中,TGF-β1激活的p38 MAPK通路參與了TGF-β1上調PAI-1的作用。

Figure 1.The effect of TGF-β1 on the expression of PAI-1 mRNA and protein in ovarian cancer cells.SKOV3(A) and HO-8910(B)cells were incubated with TGF-β1 (10 μg/L)at the indicated time points,and PAI-1 mRNA was measured by real-time PCR.SKOV3(C) and HO-8910(D)cells were incubated with TGF-β1 (10 μg/L)for 6 h,and PAI-1 protein expression was analyzed by Western blotting.Mean±SD.n=3.*P<0.05,**P<0.01 vs 0 h.圖1 TGF-β1對卵巢癌細胞PAI-1 mRNA和蛋白表達的影響

Figure 2.Effect of TGF-β1-activated p38 MAPK pathway on the expression of PAI-1 induced by TGF-β1 in ovarian cancer cells.SKOV3(A)and HO-8910(B)cells were incubated with TGF-β1(10 μg/L)for the indicated time.The protein level of p-p38 MAPK and total p38 MAPK was measured by Western blotting.SKOV3 (C)and HO-8910(D)cells were pretreated with or without SB203580 for 1 h,and then further stimulated for 4 h with TGF-β1(10 μg/L).The expression of PAI-1 mRNA was analyzed by real-time PCR and normalized to house-keeping gene GAPDH.Mean±SD.n=3.**P<0.01 vs control;#P<0.05 vs TGF-β1.圖2 TGF-β1激活的p38 MAPK通路對TGF-β1誘導PAI-1表達的影響
3 ERK與TGF-β1上調PAI-1的關系
結果顯示,在HO-8910和SKOV3細胞中,TGF-β1也能快速增加ERK的磷酸化水平(圖3A、B),但用ERK抑制劑PD98059(20 μmol/L)預處理SKOV3細胞和HO-8910細胞后,TGF-β1上調PAI-1 mRNA的作用雖然被一定程度地抑制,但差異無統計學意義(圖3C、D),表明在卵巢癌細胞中TGF-β1激活ERK通路對其上調PAI-1的作用沒有明顯影響。

Figure 3.Effect of TGF-β1-activated ERK pathway on the expression of PAI-1 mRNA induced by TGF-β1.SKOV3 (A)and HO-8910(B)cells were incubated with TGF-β1(10 μg/L)at different time points as indicated.The protein levels of p-ERK and total ERK were measured by Western blotting.SKOV3(C)and HO-8910(D)cells were pretreated with or without PD98059 for 1 then further stimulated for 4 h with TGF-β1(10 μg/L).The expression of PAI-1 mRNA was analyzed by real-time PCR and normalized to GAPDH.Mean±SD.n=3.**P<0.01 vs control.圖3 TGF-β1激活的ERK通路對TGF-β1誘導PAI-1表達的影響
至少有85%的人類卵巢癌是人類卵巢上皮細胞(ovarian surface epithelium,OSE)來源的。在每次排卵后,卵巢上皮細胞會遭受一定程度損傷,并且經歷一個修復過程,所以排卵介導的創傷和炎癥有促進細胞增殖的作用,這被認為是導致卵巢上皮細胞癌發生發展的因素之一[11]。TGF-β1不僅是一種OSE自分泌的生長因子,也是一種卵巢的旁分泌因子,在哺乳動物卵泡形成、排卵等過程中起到重要作用,還參與調節與排卵相關的傷口修復以及卵巢癌的侵襲轉移等過程[11]。TGF-β1的作用通過一對跨膜受體,即I型和II型TGF-β受體(TGF-β receptor I,TGF-βRⅠ;TGF-β receptor II,TGF-βRⅡ)以及Smad和非Smad信號通路介導。TGF-β1先與2個TGF-βRII結合,繼而與2個TGF-βRI形成異四聚體,TGF-βRII隨即磷酸化TGF-βRI并使其激活。激活的TGF-βRI磷酸化并激活細胞內的Smad2/3,后者與co-Smad (Smad4)結合形成復合物,轉入細胞核內與特定的DNA序列結合,與轉錄共激活因子相互作用,調節TGF-β1靶基因的轉錄[6]。除了上述經典的TGF-β1-Smad信號轉導通路外,TGF-β1也可以在不同細胞中激活非Smad通路,這些通路包括MAPK家族的ERK、p38 MAPK和JNK通路以及磷脂酰肌醇3-激酶(phosphatidylinositol 3-kinase,PI3K)及其下游的蛋白激酶B/AKT通路(PI3K/AKT)和小G蛋白Rho及其下游的Rho相關的蛋白激酶(Rho-associated protein kinase,ROCK)通路(Rho/ROCK)等[8-9]。這些不同的通路獨立或者通過相互之間的作用介導TGF-β1的生物學效應。
PAI-1作為纖溶酶原激活物的抑制劑,能通過抑制纖溶酶的生成,在凝血、創傷修復、炎癥和腫瘤轉移中起重要作用[1-3]。已知PAI-1在卵巢組織不同細胞中都有表達,并且影響排卵后的傷口愈合和卵巢癌的侵襲與轉移過程[4-5]。PAI-1的表達受多種激素和化學因子及其信號通路的調控,這些調控大多在轉錄水平上進行[12-13]。PAI-1是TGF-β1的靶基因,在PAI-1基因的啟動子區域含有TGF-β1下游的Smad結合元件。TGF-β1激活的Smad3和Smad4能與PAI-1啟動子中的TGF-β1反應元件結合,誘導該基因的表達[10]。除了經典的TGF-β1/Smad通路外,有報道在肝細胞中PAI-1的表達與TGF-β1激活的下游ERK通路也有關[13]。
我們前期在卵巢癌細胞中的研究表明,抑制Smad3的表達只能部分阻斷TGF-β1上調PAI-1的作用,提示TGF-β1激活的非Smad通路可能也參與了TGF-β1上調PAI-1的作用。本研究發現在卵巢癌細胞中,TGF-β1能快速激活p38 MAPK。用p38 MAPK抑制劑SB203580抑制p38 MAPK的活性,可明顯抑制TGF-β1上調PAI-1表達。TGF-β1雖然也能激活ERK,但抑制ERK的活性對TGF-β1上調PAI-1表達沒有明顯影響。以上結果表明在卵巢癌細胞中,除了TGF-β1/Smad通路外,TGF-β1激活的p38 MAPK通路也部分參與了TGF-β1上調PAI-1表達的作用。我們之前的研究發現TGF-β1有促進卵巢癌細胞與細胞外基質(extracellular cell matrix,ECM)黏附的作用[14]。而已有報道PAI-1能通過抑制ECM降解和促進ECM沉積來增強細胞與ECM的黏附[15],提示TGF-β1上調PAI-1表達可能是其促進卵巢癌細胞黏附的機制之一,這方面有待下一步工作來證明。
[1]Ghosh AK,Vaughan DE.PAI-1 in tissue fibrosis[J].J Cell Physiol,2012,227(2):493-507.
[2]Durand MK,Bodker JS,Christensen A,et al.Plasminogen activator inhibitor-I and tumour growth,invasion,and metastasis[J].Thromb Haemost,2004,91(3):438-449.
[3]黃云劍,張遠寧,王沂芹,等.PAI-1和TIMP-1基因在腎小管間質纖維化中的表達及HGF的干預作用[J].中國病理生理雜志,2004,20(9):1542-1546.
[4]Koensgen D,Mustea A,Denkert C,et al.Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer[J].Anticancer Res,2006,26(2C): 1683-1689.
[5]Liu YX.Plasminogen activator/plasminogen activator inhibitors in ovarian physiology[J].Front Biosci,2004,9: 3356-3373.
[6]Gordon KJ,Blobe GC.Role of transforming growth factorbeta superfamily signaling pathways in human disease[J].Biochim Biophys Acta,2008,1782(4):197-228.
[7]Massagué J.TGFβ in cancer[J].Cell,2008,134(2): 215-230.
[8]趙俊芳,劉成,劉成海.轉化生長因子β胞內信號轉導與Smad蛋白[J].中國病理生理雜志,2002,18(3): 321-325.
[9]Zhang YE.Non-Smad pathways in TGF-beta signaling[J].Cell Res,2009,19(1):128-139.
[10]Dennler S,Itoh S,Vivien D,et al.Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitortype 1 gene[J].EMBO J,1998,17(11):3091-3100.
[11]Wong AS,Leung PC.Role of endocrine and growth factors on the ovarian surface epithelium[J].J Obstet Gynaecol Res,2007,33(1):3-16.
[12]Ma Y,Ryu JS,Dulay A,et al.Regulation of plasminogen activator inhibitor(PAI)-1 expression in a human trophoblast cell line by glucocorticoid(GC)and transforming growth factor(TGF)-beta[J].Placenta,2002,23(10): 727-734.
[13]Wickert L,Chatain N,Kruschinsky K,et al.Glucocorticoids activate TGF-beta induced PAI-1 and CTGF expression in rat hepatocytes[J].Comp Hepatol,2007,6:5.
[14]Chen YX,Wang Y,Fu CC,et al.Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells[J].Endocr Relat Cancer,2010,17(1):39-50.
[15]Ohashi K,Yoshimoto T,Kosaka H,et al.Interferon γ and plasminogen activator inhibitor 1 regulate adhesion formation after partial hepatectomy[J].Br J Surg,2014,101(4):398-407.
Role of TGF-β1-activated p38 MAPK in up-regulation of PAI-1 expression by TGF-β1 in human ovarian cancer cells
PAN Xiao-yu1,WANG Yan2,HUANG Gao-xiang2,LU Jian2,QU Shen1
(1Department of Endocrinology,Shanghai Tenth People’s Hospital,Tongji University,Shanghai 200072,China;2Department of Pathophysiology,The Second Military Medical University,Shanghai 200443,China.E-mail:qushencn@ hotmail.com)
AIM:To investigate the relationship between up-regulation of plasminogen activator inhibitor-1 (PAI-1)expression and activation of p38 mitogen-activated protein kinase(p38 MAPK)and extracellular signal-regulated kinase(ERK)pathways by TGF-β1 in human ovarian cancer cells.METHODS:PAI-1 expression in human ovarian cancer cells treated with TGF-β1(10 μg/L)was assayed by real-time PCR and Western blotting.The activation of p38 MAPK and ERK was determined by Western blotting using phosphorylated p38 MAPK and phosphorylated ERK antibodies.Specific p38 MAPK inhibitor(SB203580)or ERK inhibitor(PD98059)was used to inhibit their activation.RESULTS:TGF-β1 up-regulated the expression of PAI-1,and activated p38 MAPK and ERK pathways in the ovarian cancer cells.Inhibition of p38 MAPK activation by SB203580 resulted in significant inhibition of the mRNA expression of PAI-1 induced by TGF-β1.However,inhibition of ERK activation did not significantly alter TGF-β1-induced increase in PAI-1 mRNA level.CONCLUSION:TGF-β1-activated p38 MAPK pathway contributes to the up-regulation of PAI-1 expression by TGF-β1 in ovarian cancer cells.
Transforming growth factor β1;Plasminogen activator inhibitor-1;p38 mitogen-activated protein kinase;Extracellular signal-regulated kinase;Ovarian neoplasms
R730.23
A
10.3969/j.issn.1000-4718.2015.02.17
1000-4718(2015)02-284-05
2014-12-04
2014-12-20
國家自然科學基金資助項目(No.31301164)
△通訊作者Tel:021-66302531;E-mail:qushencn@hotmail.com